TH Theratechnologies Inc.

Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference

Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference

MONTREAL, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer, will participate on the “Novel Targets in Oncology: Risk vs. Reward” panel, at the Cantor Oncology, Hematology & HemeOnc Conference to be held at the New York Palace Hotel, on Wednesday, September 28, 2022, at 9:00 a.m. ET, in New York City. The presentation is available only to attendees of the conference:

Along with Mr. Levesque, Chief Financial Officer, Mr. Philippe Dubuc and Chief Medical Officer, Dr. Christian Marsolais will participate in a variety of meetings during the day of the conference.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on EDGAR at .

Investor Contact:

Elif McDonald

Senior Director, Investor Relations



1-438-315-8563   

Media Contact:

Julie Schneiderman

Senior Director, Communications & Corporate Affairs



1-514-336-7800



EN
19/09/2022

Underlying

THTheratechnologies Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Theratechnologies Inc.

 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies présente à la conférence ACTHIV 2025 de nouvelles do...

Theratechnologies présente à la conférence ACTHIV 2025 de nouvelles données soulignant l’importance de prendre en charge l’excès de graisse viscérale abdominale chez les personnes vivant avec le VIH L’analyse réalisée dans le cadre de l’étude VAMOS met en évidence le lien entre l’excès de graisse viscérale abdominale et la diminution de la qualité musculaire Selon ce qu’on rapporte dans la série de cas, l’association de la tésamoréline à un agoniste des récepteurs du GLP-1 fonctionne. MONTRÉAL, 02 mai 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Sociét...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Impo...

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19th Annual American Conference for the Treatment of HIV (ACTHI...

May 2, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Provides Update on Sale Process

Theratechnologies Provides Update on Sale Process MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that following careful consideration of the current circumstances, including the publicly announced proposal from Future Pak, the Board of Directors of the Company (the “Board”) has decided to further evaluate the potential sale of the Company through an open and non-exclusive process. In connection with this determination, the Board has authorized...

April 15, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies fait le point sur le processus de vente

Theratechnologies fait le point sur le processus de vente MONTRÉAL, 15 avr. 2025 (GLOBE NEWSWIRE) -- Theratechnologies inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique au stade commercial, annonce aujourd’hui qu’après un examen attentif des circonstances actuelles, y compris la proposition annoncée publiquement de Future Pak, le conseil d’administration de la Société (le « Conseil ») a décidé d’évaluer davantage la vente potentielle de la Société au moyen d’un processus ouvert et non exclusif. Dans le cadre de cette décision, le Cons...

April 15, 2025 1 EN
 PRESS RELEASE
Free
TH Theratechnologi...

Theratechnologies Responds to Future Pak’s Press Release and Announces...

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, wishes to address its shareholders in response to a press release issued today by Future Pak, LLC (“Future Pak”) regarding its proposals to acquire the Company. The Company believes its shareholders should be aware of the following: In August 2024, the Company ...

April 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch